SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could fall after early 2027 has fueled a sharp selloff and concern about future pricing and revenue. Traders disagree over whether the warning signals sustained pressure or is only a preliminary estimate, pointing to CMSs more stable outlook while criticizing CorMedixs lack of clarification.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a sharp Nasdaq selloff tied to weakness in technology and semiconductor stocks, with traders debating whether concerns about AI spending and earnings justify more downside or whether the decline is an oversold dip to buy. The late-session rebound prompted some dip-buying optimism, but bearish traders continued to warn that the correction may not be over.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

The rally toward fresh highs is drawing attention ahead of the expected Q3 report, with traders weighing BRIUMVIs growth against unconfirmed buyout speculation and possible short-covering. Some see the move as a bet on earnings and the companys commercial prospects rather than an acquisition; no deal has been confirmed.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 AML trial reaching its prespecified 80th death event has triggered final analysis, with topline results expected this quarter. Traders are divided over whether GPS improved survival: bullish holders see the pending readout as a major catalyst, while bears question the efficacy case, and the share-price decline has intensified debate about selling pressure and alleged short activity.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 76,874.98691422 USD and is down -4.82 over the last 24 hours. It is currently trading on 12773 active market(s) with $58,826,736,014.03 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

A reported major Binance security breach and temporary withdrawal suspension have fueled Bitcoin selling and concerns about crypto exchange security. Traders disagree over whether the incident signals broader risk or is isolated to Binance, with some viewing the pullback as a buying opportunity and others warning of further downside.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor-sector selloff, with traders frequently citing Intels weak outlook and slowing PC demand, has hammered SOXL, whose 3x leverage magnifies moves. Traders are split between buying the dip and anticipating a relief bounce versus warning of further losses, with some attributing the selling to liquidations.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is caught in a broader technology and semiconductor selloff as traders question whether massive AI infrastructure spending will generate adequate returns, with mixed Amazon and Intel results adding to sector concerns. The community is split between warnings that the AI trade may be overstretched and dip buyers who view the decline as a temporary pullback while AI demand remains strong.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors upcoming FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date and the companys amended application emphasizing upper-limb function data. Bullish traders interpret the longer-term data, rare-disease policy discussions and recent commercial hiring as encouraging signs, while skeptics cite prior FDA concerns and say approval remains uncertain.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its quarterly report is fueling concern about slowing ad growth, analyst target cuts, and weakness across advertising-related stocks. Traders debate whether the decline reflects deteriorating prospects or has overshot the companys growth and cash-generation fundamentals, with earnings seen as a key test.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

IOVA is under pressure after updated lifileucel lung-cancer data showed a 24.6% response rate across 69 patients, while a retrospective biomarker-selected subgroup showed a much higher 59.1% rate; investors are weighing the subgroups promise against immature durability data and uncertainty about the broader approval path. The debate is amplified by criticism of managements presentation, with some traders viewing the selloff as an overreaction to a potentially valuable precision-treatment strategy.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

NAL New Alliance Bancshares Inc.

Latest NAL News